Syngene Gets Partial Relief in Long-Pending Tax Dispute; Expects Lower Contingent Liability

Bengaluru, January 9, 2026: Syngene International Limited (NSE: SYNGENE | BSE: 539268) has received a favourable update in a long-running tax matter related to the assessment year 2016–17, with the appellate authority partly allowing the company’s appeal and directing further verification on select claims.

Background of the Matter​

The case relates to an assessment order issued in December 2018, under which certain additions and disallowances were made, resulting in a tax demand of ₹72.34 crore. Syngene had challenged this order in early 2019.

In the latest development, the appeal has been partly allowed. The appellate authority has also instructed the assessing officer to re-examine specific claims and grant relief where found admissible.

Financial Impact and Next Steps​

Syngene stated that the order is not expected to have any material adverse impact on its financial position, operations, or business activities. Following the directions issued, the assessing officer is required to pass a consequential order giving effect to the appellate decision.

The company expects this process to lead to a reduction in contingent liabilities and may also result in a refund from the income tax department once the revised assessment is completed.

Status of Proceedings​

No penalties, restrictions, or adverse observations have been recorded in the order. Syngene has indicated that it is currently analysing the detailed implications and will take appropriate action as required.

About the Company​

Syngene International Limited is a leading contract research, development, and manufacturing services provider, offering integrated scientific services across the drug discovery, development, and manufacturing value chain. The company is listed on both the NSE and BSE and is part of the Biocon Group.




Source: